KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Debt (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Total Debt for 6 consecutive years, with $18.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt fell 32.03% year-over-year to $18.7 million, compared with a TTM value of $18.7 million through Dec 2025, down 32.03%, and an annual FY2025 reading of $18.7 million, down 32.03% over the prior year.
  • Total Debt was $18.7 million for Q4 2025 at Recursion Pharmaceuticals, down from $20.8 million in the prior quarter.
  • Across five years, Total Debt topped out at $31.0 million in Q2 2024 and bottomed at $536000.0 in Q4 2022.
  • Average Total Debt over 5 years is $10.2 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Total Debt crashed 94.45% in 2021, then soared 2586.58% in 2024.
  • Year by year, Total Debt stood at $633000.0 in 2021, then dropped by 15.32% to $536000.0 in 2022, then surged by 113.06% to $1.1 million in 2023, then soared by 2303.42% to $27.4 million in 2024, then crashed by 32.03% to $18.7 million in 2025.
  • Business Quant data shows Total Debt for RXRX at $18.7 million in Q4 2025, $20.8 million in Q3 2025, and $22.9 million in Q2 2025.